Eli Lilly's weight loss pill orforglipron clears its latest trial, paving way for approval
1. Eli Lilly's weight loss pill met trial goals, enabling global approval filing. 2. Orforglipron showed notable weight loss, 10.5% at highest dose in 72 weeks. 3. The drug may provide easier access compared to existing GLP-1 injections. 4. Higher dose had a 10.6% discontinuation rate due to side effects. 5. Lilly expects to launch the pill globally within a year.